Sentigen receives patent for cell-based drug discovery

By Elaine Rigoli

Tampa, Fla., June 14 - Sentigen Holding Corp. has been issued U.S. Patent No. 7,045,281 entitled "Method for Using Division Arrested Cells in Screening Assays," covering the generation and application of Division Arrested Assay Ready Cells in drug discovery.

"This patent clearly demonstrates the company's strategic commitment to scientists engaged in cell-based drug discovery by providing an 'off the shelf' source of consistent high quality cells," chief executive officer Thomas Livelli said in a news release.

"We believe Division Arrested Assay Ready Cells have the potential to broadly impact cell-based drug discovery by turning cells into validated reagents and the company plans to aggressively promote their use," he added.

Sentigen said the cells are designed to reduce the need to engage in costly ongoing cell culture operations to support cell-based drug discovery, effectively uncoupling the process of cell production from drug screening.

Sentigen, based in Phillipsburg, N.J., conducts business through two wholly owned operating subsidiaries: Cell & Molecular Technologies, Inc. and Sentigen Biosciences, Inc.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.